Is Dutch Govt Pursuing Wider EU Discussion And Collaboration On Pricing and Reimbursement?
An initiative from the Netherlands to ensure that pharmaceutical companies market centrally approved medicines in all EU member states is probably intended to fuel discussions on the differences in national pricing and reimbursement policies, says a legal expert.
You may also be interested in...
The BeNeLuxA initiative for improving access to medicines could soon include more countries, but much about the collaboration remains opaque for the pharmaceutical industry. Lawyer Koosje van Lessen Kloeke says constructive dialogue between the initiative and industry would benefit the collaboration.
The BeNeLuxA collaboration for sustainable access to medicines may soon expand further. Future partners could include France and non-EU markets.
England’s health technology appraisal body, NICE, and the UK medicines regulator, the MHRA, are working together to align their process timelines so that access to medicines is “maintained and enhanced.”